To address this pivot biological relevance, alteration-matched EGFR tyrosine kinase inhibitors (erlotinib or osimertinib) and salinomycin, a potassium ionophore with EMT-specific toxicity (Gupta et al., 2009), were respectively assessed in parental and TGFβ-stimulated lung cancer models. Here, TGFB1 is linked to lung carcinoma.